Morepen Laboratories Limited (MOREPENLAB) fundamentals
Morepen Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MOREPENLAB (ISIN INE083A01026). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Morepen Laboratories Limited does
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Valuation and market data
| Last close | ₹115.78 |
|---|---|
| Market capitalisation | ₹6,211 crore |
| Enterprise value | ₹6,274 crore |
| P/E (TTM) | 0.00 |
| Price to book | 5.23 |
| Price to sales (TTM) | 3.15 |
| Book value per share | ₹22.13 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Nov 24 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,703 crore | ₹89 crore | ₹66 crore | 0.00 |
| Mar 2025 | ₹1,570 crore | ₹138 crore | ₹102 crore | 1.90 |
| Mar 2024 | ₹1,550 crore | ₹149 crore | ₹111 crore | 2.17 |
| Mar 2023 | ₹1,345 crore | ₹63 crore | ₹46 crore | 0.92 |
| Mar 2022 | ₹1,460 crore | ₹126 crore | ₹101 crore | 2.25 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 35.6% |
|---|---|
| Foreign institutions (FII) | 1.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 1.3% |
| Retail and others | 61.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.